Several CDK4/6 inhibitors have been approved for metastatic breast cancer [73] and phase I/II trials combining MEK or ERK inhibitors with the CDK4/6 inhibitor palbociclib in KRAS-mutant tumours are ongoing. This evidence concerns the gene KRAS and neoplasm.